In current European and American revascularization guidelines, RA grafts are now strongly endorsed as the second conduit for ...
The Calcium Channel Blockers Market was valued at US$ 14.5 Bn in 2022 and is projected to grow at a CAGR of 5.7% from 2023 to ...
"We prevented calcium influx by inhibiting L-Type Calcium Channel (LTCC), a protein that regulates calcium in these cells. Our findings suggest that LTCC could be a target for developing new ...
Do you ever you wake up once, twice or more during the night to pee? These nighttime wakeups are common but not unsolvable.
A recent study has raised concerns about a widely used blood pressure medication called Calcium Channel Blockers (CCBs).
Milestone Pharmaceuticals faces a pivotal FDA PDUFA decision for etripamil in PSVT. Read here for a detailed investment ...
"We prevented calcium influx by inhibiting L-Type Calcium Channel (LTCC), a protein that regulates calcium in these cells. Our findings suggest that LTCC could be a target for developing new ...
Patients with diabetic kidney disease (DKD) and anemia have no worse, and possibly better, cardiovascular outcomes from finerenone treatment.
Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and resistant hypertension.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback